FrancophonIA/ELRC3.0 huggingface dataset:
English: GEP-NETs are cancers which start in types of cells in the gut or pancreas that normally release hormones.
Croatian: GEP-NET su karcinomi koji se razvijaju u vrstama stanica u crijevima ili gušterači koje normalno otpuštaju hormone.
English: Some studies looked at the sensitivity of the PET scans (how well the scans identified patients who had GEP-NETs or their metastases), some analysed specificity (how reliable scans were at identifying subjects who had no GEP-NETs) and some looked at lesion detection rate (how good scans were at identifying the tumours).
Croatian: U nekim od ispitivanja promatrala se osjetljivost PET snimaka (koliko su dobro snimke identificirale bolesnike koji su imali GEP-NET stanice ili metastaze), u nekima se proučavala specifičnost (pouzdanost snimaka u utvrđivanju slučajeva u kojima nije bilo GEP-NET stanica), a u nekima se promatrala stopa otkrivanja tumora (uspješnost snimaka u utvrđivanju tumora).
English: The full EPAR for SomaKit TOC can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek SomaKit TOC nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of SomaKit TOC have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka SomaKit TOC nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for SomaKit TOC can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Sažetak mišljenja Odbora za rijetke bolesti o lijeku SomaKit TOC možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: SomaKit TOC is a diagnostic medicine used in adult patients who are thought to have so-called welldifferentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Croatian: SomaKit TOC je dijagnostički lijek koji se primjenjuje u odraslih bolesnika za koje se smatra da imaju takozvane dobro diferencirane gastroenteropankreatične neuroendokrine tumore (GEP-NET).
English: What is SomaKit TOC and what is it used for?
Croatian: Što je SomaKit TOC i za što se koristi?
English: Not all cells have these receptors but most welldifferentiated GEP-NET cells have high amounts on their surface.
Croatian: Ti se receptori ne nalaze na svim stanicama, ali su prisutni u velikim količinama na površini većine dobro diferenciranih GEP-NET stanica.
English: For localising the primary GEP-NET, one study showed that the medicine had a sensitivity of 45% compared with 10% in patients given another approved diagnostic medicine, indium (111In) pentetreotide, and this was confirmed by another study that showed that the former had better sensitivity.
Croatian: U lokaliziranju primarnih GEP-NET tumora jedno je ispitivanje pokazalo da lijek ima 45 % osjetljivosti, u usporedbi s 10 % u bolesnika koji su primili drugi odobreni dijagnostički lijek, indij (111In) pentetreotid, što je potvrdilo drugo ispitivanje koje je dokazalo veću osjetljivost lijeka SomaKit TOC.
English: It is not intended to provide practical advice on how to use SomaKit TOC.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka SomaKit TOC.
English: After SomaKit TOC is radiolabelled it emits a small amount of radiation which poses a low risk of cancer or hereditary abnormalities.
Croatian: Nakon radioaktivnog obilježavanja lijek SomaKit TOC emitira malu količinu zračenja, što predstavlja mali rizik od razvoja karcinoma ili nasljednih poremećaja.
English: The prepared medicine, radiolabelled with gallium (68Ga) chloride, attaches to these receptors on the GEP-NET cells.
Croatian: Pripremljen lijek, radioaktivno obilježen galijevim (68Ga) kloridom, veže se na te receptore na GEP-NET stanicama.
English: For more information about treatment with SomaKit TOC, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom SomaKit TOC pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: SomaKit TOC is available as a kit for preparing a solution for injection.
Croatian: Lijek SomaKit TOC dostupan je kao set za pripremu otopine za injekciju.
English: The resulting build-up of radiation can be detected by the special camera of the PET scan.
Croatian: Posljedica je rast radioaktivnosti, što se otkriva posebnom PET kamerom.
English: The risks of side effects seemed to be low and the CHMP therefore decided that SomaKit TOC's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Budući da smatra da su rizici od nuspojava mali, CHMP je zaključio da koristi lijeka SomaKit TOC nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: Other information about SomaKit TOC
Croatian: Ostale informacije o lijeku SomaKit TOC
English: SomaKit TOC contains the active substance edotreotide.
Croatian: Lijek SomaKit TOC sadržava djelatnu tvar edotreotid.
English: What are the risks associated with SomaKit TOC?
Croatian: Koji su rizici povezani s lijekom SomaKit TOC?
English: SomaKit TOC can only be obtained with a prescription and the injection must only be prepared and given in a suitable facility by experts in handling radioactive medicines.
Croatian: Lijek SomaKit TOC izdaje se samo na liječnički recept, a injekciju mogu pripremiti i ubrizgati samo zdravstveni radnici s iskustvom u radu s radioaktivnim lijekovima i u odgovarajućim ustanovama.
English: SomaKit TOC is used with a technique called positron emission tomography (PET scan) to obtain images that locate the cancers.
Croatian: Lijek SomaKit TOC primjenjuje se u kombinaciji s tehnikom naziva pozitronska emisijska tomografija (PET) kako bi se dobile slike kojima se lociraju karcinomi.
English: Why is SomaKit TOC approved?
Croatian: Zašto je lijek SomaKit TOC odobren?
English: The active substance in SomaKit TOC, edotreotide, attaches specifically to receptors called somatostatin receptors on the surface of cells.
Croatian: Djelatna tvar u lijeku SomaKit TOC, edotreotid, veže se specifično na receptore naziva somatostatinski receptori na površini stanica.
English: For practical information about using SomaKit TOC, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka SomaKit TOC bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: For the full list of side effects or restrictions with SomaKit TOC, see the package leaflet.
Croatian: Potpuni popis nuspojava ili ograničenja zabilježenih pri primjeni lijeka SomaKit TOC potražite u uputi o lijeku.
English: The active substance in SomaKit TOC, edotreotide radiolabelled with gallium (68Ga) chloride, has a well established use in detecting GEP-NETs.
Croatian: Uporaba djelatne tvari u lijeku SomaKit TOC, edotreotida radioaktivno obilježenog galijevim (68Ga) kloridom, ustanovljena je u otkrivanju GEP-NET stanica.
English: How is SomaKit TOC used?
Croatian: Kako se SomaKit TOC koristi?
English: What benefits of SomaKit TOC have been shown in studies?
Croatian: Koje su koristi lijeka SomaKit TOC dokazane u ispitivanjima?
English: How does SomaKit TOC work?
Croatian: Kako djeluje SomaKit TOC?
English: Ga) chloride had a sensitivity and specificity of 100% and 89% respectively, and found a lesion detection rate of 75%.
Croatian: Rezultati daljnjih ispitivanja pokazali su da edotreotid obilježen galijevim (68Ga) kloridom ima osjetljivost 100 % i specifičnost 89 % te su ustanovili da je stopa otkrivanja tumora 75 %.
English: Frequency ‘not known': aggression
Croatian: Učestalost „nepoznata": agresija
English: Adopted at the 9-12 March 2015 PRAC
Croatian: Usvojeno na sjednici PRAC-a 9. - 12. ožujka 2015.
English: Having considered the available evidence in the literature and from individual case safety reports, the PRAC has agreed that the MAH(s) of aripiprazole-containing medicinal products should submit a variation within 2 months, to amend the product information as described below (new text underlined).
Croatian: Nakon razmatranja dostupnih dokaza iz literature i iz sigurnosnih izvješća o pojedinačnom slučaju, PRAC je zaključio da nositelj(i) odobrenja za lijekove koji sadrže aripiprazol trebaju podnijeti izmjenu u roku od 2 mjeseca kako bi se izmijenile informacije o lijeku na način opisan u nastavku teksta (novi tekst je podcrtan).
English: The PRAC has further agreed that the MAH for Abilify and Abilify Maintena should submit in the next PSUR (data lock point 16/07/2015), a cumulative review of aripiprazole overdose and the risk of aggression and related events.
Croatian: PRAC je dalje zaključio da nositelj odobrenja za lijekove Abilify i Abilify Maintena treba podnijeti u sljedećem periodičkom izvješću o neškodljivosti (PSUR) (datum zaključavanja baze podataka 16.7.2015.), kumulativni pregled predoziranja aripiprazolom te rizika od agresije i povezanih događaja.
English: The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known: Aggression
Croatian: Od stavljanja u promet oralnog aripiprazola prijavljene su sljedeće nuspojave, ali njihova učestalost nije poznata: Agresija
English: Aripiprazole - Aggression and related events (EPITT no
Croatian: Aripiprazol - agresija i povezani događaji (EPITT br. 18127)
English: Package Leaflet:
Croatian: - Nuspojave:
English: Section 4.8 - Undesirable effects:
Croatian: Dio 4.8.
English: EU/1/04/295/001
Croatian: EU/1/04/295/001 Xagrid
English: Invented name Strength Pharmaceutical Form Route of administration Packaging Package size
Croatian: Farmaceutski oblik Put primjene
English: Xagrid
Croatian: Jačina
English: Bottle (HDPE) 100 capsules
Croatian: Bočica (HDPE)
English: 0.5 mg Capsule, hard
Croatian: Kapsula, tvrda
English: Oral use
Croatian: Pakiranje
English: Irbesartan/hydrochlorothiazide
Croatian: Ifirmacombi irbesartan/hidroklorotiazid
English: This means that Ifirmacombi is similar to a ‘reference medicine' already authorised in the European Union (EU) called CoAprovel.
Croatian: To znači da je Ifirmacombi sličan „referentnom lijeku” koji je već odobren u Europskoj uniji pod nazivom CoAprovel.
English: What are the benefits and risks of Ifirmacombi?
Croatian: Koje su koristi i rizici od lijeka Ifirmacombi?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ifirmacombi.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu lijeka Ifirmacombi.
English: It is available as tablets (150 mg irbesartan and 12.5 mg hydrochlorothiazide; 300 mg irbesartan and 25 mg hydrochlorothiazide; 300 mg irbesartan and 12.5 mg hydrochlorothiazide).
Croatian: Dostupan je u obliku tableta (150 mg irbesartana i 12,5 mg hidroklorotiazida; 300 mg irbesartana i 25 mg hidroklorotiazida; 300 mg irbesartana i 12,5 mg hidroklorotiazida).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ifirmacombi on 4 March 2011.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Ifirmacombi vrijedi na prostoru Europske unije od 4. ožujka 2011.
English: The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Croatian: Kombinacija dviju djelatnih tvari ima kumulativno djelovanje tako što snižava krvni tlak više nego svaki lijek pojedinačno.
English: Ifirmacombi may be added to other treatments for hypertension.
Croatian: Ifirmacombi se može dodati nekim drugim načinima liječenja hipertenzije.
English: By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.
Croatian: Blokiranjem receptora na koje se angiotenzin II inače veže, Irbesartan sprečava djelovanje hormona, čime omogućava širenje krvnih žila.
English: It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.
Croatian: Djeluje kroz pojačano mokrenje, čime smanjuje količinu tekućine u krvi i snižava krvni tlak.
English: Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended.
Croatian: Ne preporučuju se doze veće od 300 mg irbesartana i 25 mg hidroklorotiazida jedanput na dan.
English: Other information about Ifirmacombi
Croatian: Ostale informacije o lijeku Ifirmacombi
English: The dose of Ifirmacombi to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before.
Croatian: Doza lijeka Ifirmacombi koja se primjenjuje ovisi o dozi irbesartana ili hidroklorotiazida koju je bolesnik uzimao prije.
English: Ifirmacombi is a ‘generic medicine'.
Croatian: Ifirmacombi je „generički lijek”.
English: Because Ifirmacombi is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Ifirmacombi generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: What is Ifirmacombi?
Croatian: Što je Ifirmacombi?
English: Why has Ifirmacombi been approved?
Croatian: Zašto je lijek Ifirmacombi odobren?
English: The CHMP concluded that, in accordance with EU requirements, Ifirmacombi has been shown to have comparable quality and to be bioequivalent to CoAprovel.
Croatian: CHMP je zaključio kako, u skladu s preduvjetima EU-a, lijek Ifirmacombi posjeduje usporedivu kvalitetu te je bioekvivalentan lijeku CoAprovel.
English: This is a summary of the European public assessment report (EPAR) for Ifirmacombi.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Ifirmacombi.
English: The full EPAR for Ifirmacombi can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Ifirmacombi nalazi se na internetskim stranicama Agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Više informacija o terapiji lijekom Ifirmacombi pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: Ifirmacombi is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone.
Croatian: Ifirmacombi se koristi kod odraslih bolesnika s esencijalnom hipertenzijom (visokim krvnim tlakom) koja se ne može na odgovarajući način kontrolirati samo irbesartanom ili samo hidroklorotiazidom. „Esencijalna” znači da ne postoji očiti uzrok hipertenzije.
English: Ifirmacombi is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.
Croatian: Ifirmacombi je lijek koji sadrži dvije djelatne tvari, irbesartan i hidroklorotiazid.
English: Because Ifirmacombi is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, CoAprovel.
Croatian: Budući da je Ifirmacombi generički lijek, ispitivanja na bolesnicima bila su ograničena na utvrđivanje činjenice je li riječ o bioekvivalentu referentnom lijeku CoAprovel.
English: The Committee recommended that Ifirmacombi be given marketing authorisation.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Ifirmacombi u EU-u.
English: What is Ifirmacombi used for?
Croatian: Za što se Ifirmacombi koristi?
English: Ifirmacombi contains two active substances, irbesartan and hydrochlorothiazide.
Croatian: Ifirmacombi sadrži dvije djelatne tvari, irbesartan i hidroklorotiazid.
English: Therefore, the CHMP's view was that, as for CoAprovel, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a kako koristi nadmašuju utvrđene rizike, kao i kod lijeka CoAprovel.
English: How is Ifirmacombi used?
Croatian: Kako se Ifirmacombi koristi?
English: How does Ifirmacombi work?
Croatian: Kako djeluje Ifirmacombi?
English: How has Ifirmacombi been studied?
Croatian: Kako je Ifirmacombi ispitivan?
English: The company will also carry out studies to further characterise this risk.
Croatian: Tvrtka će provesti ispitivanja kako bi dodatno okarakterizirala rizik.
English: Rienso ferumoxytol
Croatian: Rienso ferumoksitol
English: Depending on the severity of the anaemia and the patient's body weight, a second infusion may be given two to eight days after the first dose.
Croatian: Ovisno o težini anemije i bolesnikovoj tjelesnoj težini, druga se infuzija može dati dva do osam dana nakon prve doze.
English: The full EPAR for Rienso can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o ocjeni dokumentacije (EPAR) o lijeku Rienso nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as a solution for infusion (drip) into a vein.
Croatian: Dostupan je kao otopina za infuziju (drip) u venu.
English: In all three studies, patients taking Rienso had higher average increases in haemoglobin: 1.2 g/dl versus 0.5 g/dl; 0.8 g/dl versus 0.2 g/dl; and 1.0 g/dl versus 0.5 g/dl.
Croatian: U sva tri ispitivanja bolesnici koji su uzimali Rienso imali su više prosječne poraste u razini hemoglobina: 1,2 g/dl naspram 0,5 g/dan; 0,8 g/dl naspram 0,2 g/dl i 1,0 g/dl naspram 0,5 g/dl.
English: Patients should have their blood and iron levels tested after at least one month following treatment.
Croatian: Bolesnicima treba testirati krv i razine željeza najmanje mjesec dana nakon liječenja.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rienso on 15 June 2012.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Rienso na snazi u Europskoj uniji od 15. lipnja 2012.
English: In studies with Rienso, side effects were seen in 7.9% of patients taking the medicine, of which 0.2% were considered serious.
Croatian: U ispitivanjima s lijekom Rienso nuspojave su uočene u 7,9% bolesnika koji su uzimali lijek od kojih se njih 0,2% smatra ozbiljnim.
English: Serious cases of hypersensitivity (allergic reaction) or hypotension were uncommon and were seen in 0.2% of patients.
Croatian: Ozbiljni slučajevi preosjetljivosti (alergijska reakcija) ili hipotenzija bili su manje česti i uočeni su kod 0,2% bolesnika.
English: The most frequently reported side effects were symptoms affecting the gut (diarrhoea, constipation, nausea and vomiting), headache, dizziness and hypotension (low blood pressure), all occurring in less than 2.5% of patients.
Croatian: Najčešće prijavljene nuspojave bili su simptomi koji su zahvaćali želudac (proljev, zatvor, mučnina i povraćanje), glavobolja, omaglica i hipotenzija (nizak tlak krvi), a sve su dogodile u manje od 2,5% bolesnika.
English: Rienso is given as an infusion into a vein lasting at least 15 minutes.
Croatian: Rienso se daje u obliku infuzije u venu koja traje najmanje 15 minuta.
English: The doctor should ensure that the patient is observed for adverse reactions for at least 30 minutes following the infusion.
Croatian: Liječnik mora osigurati da bolesnik bude pod nadzorom zbog moguće pojave nuspojava tijekom najmanje 30 minuta nakon infuzije.
English: The main measure of effectiveness was how much haemoglobin levels (measured in grams per decilitre, g/dl) rose after five weeks.
Croatian: Glavna mjera djelotvornosti bila je porast razine hemoglobina (mjereno u gramima po decilitru, g/dl) nakon pet tjedana.
English: When injected into the blood, it is taken up by cells in the liver, spleen and the bone marrow, at which point the iron is released from the compound and replaces the body's depleted iron stores.
Croatian: Kad se injicira u krv, unosi se u stanice jetre, slezene i koštane srži pri čemu se željezo oslobađa iz spoja i zamjenjuje potrošene zalihe željeza u tijelu.
English: The increase in haemoglobin seen in the main studies was considered by the CHMP to be a valuable improvement and comparable to what is obtained with standard intravenous iron preparations.
Croatian: Porast u razini hemoglobina uočen u glavnim ispitivanjima CHMP je smatrao dragocjenim poboljšanjem te usporedivim s onim što se dobiva sa standardnim pripravcima željeza.
English: This is a summary of the European public assessment report (EPAR) for Rienso.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Rienso.
English: With the iron stores replenished, the body can produce more haemoglobin, which will help correct the anaemia.
Croatian: Kad se zalihe željeza potroše tijelo može proizvesti više hemoglobina što će pomoći u korekciji anemije.
English: What measures are being taken to ensure the safe and effective use of Rienso?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rienso?
English: Other information about Rienso
Croatian: Ostale informacije o lijeku Rienso
English: For more information about treatment with Rienso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Rienso pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: It must not be used in patients with evidence of excess iron in the body or in patients whose anaemia is not caused by iron deficiency.
Croatian: Ne smije se koristiti u bolesnika s dokazom suviška željeza u tijelu ili kod bolesnika čija anemija nije uzrokovana nedostatkom željeza.
English: Rienso must not be used in people with a history of drug allergy, including allergy to ferumoxytol or any other iron preparation.
Croatian: Rienso se ne smije koristiti kod ljudi s anamnezom alergije na lijek, uključujući i alergiju na ferumoksitol ili na bilo koji drugi pripravak željeza.
English: A risk management plan has been developed to ensure that Rienso is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Rienso.
English: Rienso is used to treat anaemia (low levels of red blood cells or haemoglobin) caused by a deficiency of iron in patients with chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly).
Croatian: Rienso se koristi za liječenje anemija (niskih razina crvenih krvnih stanica ili hemoglobina uzrokovanih nedostatkom željeza u bolesnika s kroničnom bolešću bubrega (dugotrajno, progresivno smanjenje sposobnosti normalnog rada bubrega).
English: Three main studies involving 838 chronic kidney disease patients with iron deficiency anaemia have been carried out to compare Rienso with an iron treatment taken by mouth.
Croatian: Provedena su tri glavna ispitivanja koja su uključivala 838 kroničnih bolesnika s bolešću bubrega koji su imali nedostatak željeza kako bi se usporedio Rienso s terapijom peroralnim željezom.
English: Iron deficiency is a common cause of anaemia in patients with long-term kidney disease and is itself caused by many factors including the poor absorption of dietary iron from food.
Croatian: Nedostatak željeza je čest uzrok anemije u bolesnika s dugotrajnom bolešću bubrega te je sam uzrokovan mnogim čimbenicima uključujući i slabu apsorpciju željeza iz prehrambenih namirnica.
English: What is Rienso?
Croatian: Što je Rienso?